HONG KONG – Alecensa (alectinib, Genentech/Roche AG) has been shown to be safe and effective in Asian patients, having shown superiority to the ALK Inhibitor Xalkori (crizotinib, Pfizer Inc.), in a phase III trial as a first-line treatment in Japanese patients with advanced or recurrent ALK-positive non-small-cell lung cancer (NSCLC).